Rheumatology Therapeutics Market Report 2026

Rheumatology Therapeutics Market Overview

• Rheumatology Therapeutics market size has reached to $44.18 billion in 2025 • Expected to grow to $54.16 billion in 2030 at a compound annual growth rate (CAGR) of 4.1% • Growth Driver: Increasing Autoimmune Disease Prevalence Drives Rheumatology Therapeutics Market Growth • Market Trend: Advancements In Intravenous (IV) Formulations In Rheumatology Therapeutics • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Rheumatology Therapeutics Market?

Rheumatology therapeutics encompass treatments aimed at managing and alleviating symptoms of rheumatic diseases, such as arthritis, lupus, and gout. These therapies include medications, such as anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs), and biologics, as well as physical therapy and lifestyle modifications. The goal is to reduce inflammation, control pain, and improve the quality of life for patients. The main rheumatology therapeutics are disease-modifying anti-rheumatic drugs, nonsteroidal anti-inflammatory drugs, corticosteroids, uric acid drugs, and others. Disease-modifying anti-rheumatic drugs (DMARDs) refer to a class of medications designed to slow or alter the underlying disease process in rheumatoid arthritis and other autoimmune conditions rather than just alleviate symptoms. It is sold through hospital pharmacies, retail pharmacies, and online pharmacies, and it is used for rheumatoid arthritis, osteoarthritis, gout, psoriatic arthritis, ankylosing spondylitis, and others.

What Is The Rheumatology Therapeutics Market Growth Forecast?

The rheumatology therapeutics market size is expected to see steady growth in the next few years. It will grow to $54.16 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to rising demand for biologic dmards, increasing aging population with chronic joint disorders, growing awareness of early diagnosis and treatment, expansion of targeted synthetic dmards, increasing healthcare expenditure on chronic disease management. Major trends in the forecast period include growing adoption of biologic and targeted dmards, shift toward early and aggressive disease management, rising use of combination therapies in rheumatic diseases, increasing focus on long-term disease remission, expansion of personalized treatment approaches in rheumatology.

Global Rheumatology Therapeutics Market Segmentation

1) By Drug Class: Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Other Drugs Classes 2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 3) By Disease Indication: Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Ankylosing Spondylitis, Other Disease Indications Subsegments: 1) By Disease Modifying Anti-Rheumatic Drugs (DMARDs): Conventional Synthetic DMARDs, Biologic DMARDs, Targeted Synthetic DMARDs 2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): COX-2 Inhibitors, Traditional NSAIDs 3) By Corticosteroids: Oral Corticosteroids, Injectable Corticosteroids, Topical Corticosteroids 4) By Uric Acid Drugs: Uric Acid Lowering Agents, Uricosuric Agents, Pegloticase 5) By Other Drug Classes: Immunosuppressants, Biologic Therapies, Analgesics

What Is The Driver Of The Rheumatology Therapeutics Market?

The rising prevalence of autoimmune diseases is expected to propel the growth of the rheumatology therapeutics market going forward. An autoimmune disease is a condition where the immune system mistakenly attacks and damages the body's tissues. The prevalence of autoimmune diseases is growing due to a combination of genetic, environmental, and lifestyle factors, including increased awareness and improved diagnostic capabilities. Rheumatology therapeutics are required for autoimmune diseases to manage inflammation, alleviate symptoms, and prevent joint and tissue damage caused by the immune system attacking the body. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, around 514,000 people in Australia, or 2.0% of the population, were estimated to be living with rheumatoid arthritis in 2022. Rheumatoid arthritis accounted for 2.0% of the total disease burden and 16% of the burden for all musculoskeletal conditions in 2023. Therefore, the rising prevalence of autoimmune diseases is driving the growth of the rheumatology therapeutics industry.

Key Players In The Global Rheumatology Therapeutics Market

Major companies operating in the rheumatology therapeutics market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., UCB S.A., Sanofi SA, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Janssen Biotech, Genentech Inc., Galapagos NV

Global Rheumatology Therapeutics Market Trends and Insights

Major companies operating in the rheumatology therapeutics market are developing innovative solutions, such as intravenous (IV) formulations, to enhance treatment efficacy and patient convenience. An intravenous (IV) formulation refers to a medication or substance that is administered directly into a vein through a needle or catheter. For instance, in October 2023, Novartis AG, a Switzerland-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) had approved Cosentyx, an intravenous (IV) formulation. This form of Cosentyx is uniquely approved to treat adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). It works by specifically targeting and inhibiting interleukin-17A (IL-17A) and is the only non-tumor necrosis factor alpha (TNF-α) IV treatment available for these conditions.

What Are Latest Mergers And Acquisitions In The Rheumatology Therapeutics Market?

In February 2024, Alfasigma S.p.A., an Italy-based pharmaceutical company, acquired the Jyseleca (filgotinib) business from Galapagos NV for $184.54 million. Through the acquisition, Alfasigma has expanded its product portfolio with an innovative pharmaceutical targeting gastrointestinal and rheumatological treatments. The acquisition also bolsters Alfasigma's presence in European markets by integrating Jyseleca's business, which includes marketing authorizations across Europe and the UK, along with operations in commercialization, medical affairs, and development. Galapagos NV is a Belgium-based manufacturer of rheumatology therapeutics.

Regional Insights

North America was the largest region in the rheumatology therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Rheumatology Therapeutics Market?

The rheumatology therapeutics market consists of revenues earned by entities by providing services such as diagnostic services, telemedicine, rehabilitation services, and lifestyle and nutritional counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The rheumatology therapeutics market also includes sales of biologic response modifiers, janus kinase (JAK) inhibitors, analgesics, and immunosuppressants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Rheumatology Therapeutics Market Report 2026?

The rheumatology therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the rheumatology therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.